TrialCardiovascular diabetology2014

Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study.

Kohei Kaku et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.